Zimmer Holdings is a global leader in the development and manufacture of orthopaedic implants and related products, focusing on enhancing the quality of life for individuals suffering from conditions related to bones and joints. The company specializes in a wide range of surgical products and services, including joint replacement systems, trauma products, and a variety of surgical instruments. Zimmer Holdings also invests in innovative technologies and solutions to improve surgical outcomes and patient satisfaction, catering to healthcare professionals and institutions worldwide. With a commitment to advancing orthopaedic care, the company plays a crucial role in both the medical community and patient rehabilitation processes. Read More
Shares of medical device company Zimmer Biomet (NYSE:ZBH)
fell 10.2% in the afternoon session after the company reported underwhelming first quarter 2025 results as it lowered its full-year EPS guidance. A key takeaway was the weak growth. Sales were up just 1% as demand for some product lines came in weaker. While hips and trauma gear did well, others, like bone cement and surgical tools, dropped nearly 5%. Overall, this was a softer quarter.
Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services sector, raising doubts about near-term rate cuts and weighing on risk appetite.
US services sector growth slows in April. Inflationary pressures surge to a 2-year high, driven by trade tariffs. Stalling momentum and stagflation risks loom.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Medical device company Zimmer Biomet (NYSE:ZBH) announced better-than-expected revenue in Q1 CY2025, with sales up 1.1% year on year to $1.91 billion. Its non-GAAP profit of $1.81 per share was 2.3% above analysts’ consensus estimates.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 12.7%. This drop was worse than the S&P 500’s 7.5% loss.
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
Wall Street gained ground by midday trading on Tuesday, as investor concerns over the economic impact of trade tensions continued to ease following recent signs that the Trump administration was taking a more conciliatory approach.
Zimmer Biomet has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $101.84. However, the stock is beating the S&P 500’s 9.8% decline during that period.
